Cidofovir: Difference between revisions
m Protected "Cidofovir": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
Gerald Chi (talk | contribs) m Changed protection level for "Cidofovir" ([Edit=Allow only autoconfirmed users] (expires 15:54, 7 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 15:54, 7 January 2014 (UTC))) |
(No difference)
|
Revision as of 15:54, 31 December 2013
File:Cidofovir.png | |
Clinical data | |
---|---|
Pregnancy category |
|
Routes of administration | intravenous |
ATC code | |
Pharmacokinetic data | |
Bioavailability | complete |
Protein binding | 6% |
Elimination half-life | 2.4 to 3.2 hours |
Excretion | renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C8H14N3O6P |
Molar mass | 279.187 g/mol |
Specific rotation | -97.3 |
Melting point | 260 °C (500 °F) |
Cidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA synthesis.
Cidofovir demonstrated a statistically significant effect in delaying the progression of CMV retinitis lesions in newly diagnosed patients, as well as in previously treated patients who had failed other therapies. Maintenance therapy with cidofovir involves an infusion only once every two weeks, making it a convenient treatment option. Because dosing is relatively infrequent, a permanent catheter is not necessary for infusions. The major side effect of cidofovir is that it can be nephrotoxic.
- Cidofovir has also been investigated as a treatment for progressive multifocal leukoencephalopathy, but as of 2005 studies are inconclusive.
- Cidofovir might have anti-smallpox efficacy and might be used on a limited basis in the event of a bioterror incident involving smallpox cases.
- Cidofovir shows anti-BK virus activity in a subgroup of transplant patients.
- Cidofovir is being investigated as a complementary intralesional therapy during laryngo- and bronchoscopic excision of papillomatosis caused by HPV.
Cidofovir was developed by Gilead Sciences and is marketed with the brand name Vistide by Gilead in the USA, and by Pfizer elsewhere.
- Pages with script errors
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Gilead Sciences
- Antivirals
- Antimicrobial stubs